Northern Trust
RAPP

Northern Trust’s Rapport Therapeutics RAPP Stock Holding History

Northern Trust’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6M Buy
277,305
+39,313
+17% +$1.44M ﹤0.01% 2138
2026
Q1 		$7.45M Buy
237,992
+17,177
+8% +$483K ﹤0.01% 2242
2025
Q4 		$6.7M Buy
220,815
+66,958
+44% +$1.85M ﹤0.01% 2302
2025
Q3 		$4.57M Buy
153,857
+37,584
+32% +$670K ﹤0.01% 2551
2025
Q2 		$1.32M Sell
116,273
-11,810
-9% -$125K ﹤0.01% 3233
2025
Q1 		$1.28M Buy
128,083
+55,257
+76% +$717K ﹤0.01% 3167
2024
Q4 		$1.29M Buy
72,826
+614
+0.9% +$13.6K ﹤0.01% 3269
2024
Q3 		$1.48M Buy
+72,212
New +$1.55M ﹤0.01% 3166

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Northern Trust's RAPP Position: Q2 2026 in Review

Northern Trust increased its Rapport Therapeutics (RAPP) stake by 17% in Q2 2026, buying an estimated $1.44M and bringing the position to 277,305 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2138.

Northern Trust first reported a position in RAPP in Q3 2024 and has held it in 8 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Northern Trust held 277,305 shares of Rapport Therapeutics worth $11.6M as of Q2 2026.
  • Northern Trust bought 39,313 Rapport Therapeutics shares in Q2 2026, an estimated $1.44M.
  • Rapport Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2138 holding.
  • Northern Trust first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.